Strasbourg, France, 15 December 2023 – Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologics and cell and gene therapy production from research to commercial grade has inked a collaboration with pioneering Korean cell and gene therapy (CGT) CDMO, MarkHerz to set new CGT efficiency standards focused on decreasing cost and increasing quality per dose of a therapeutic product.
The teams will work to improve process efficiency leveraging Polyplus products and expertise with Mark Herz manufacturing capabilities. Proprietary e-Zyvec® technology will be used to design tailor-made plasmids for high purity manufacturing. Plasmid engineering and production services will initiate the project, followed by upstream optimization.
“Because every CGT process is unique, we believe that working with plasmids optimized to each process should greatly impact yield and quality. Working with a team like Polypus that understands both the intricacies of how critical materials work with one another and how to solve the scientific and process challenges is key for our customers success,” said Seungmin Lee, CEO at Mark Herz. “The FAS and Scientific support teams at Polyplus will align with the Process Development team here at Mark Herz to optimize each process. Work will be performed across serotypes to collect data that is used to fine tune critical process parameters.”
“This is a first collaboration for the Polyplus team focused on the impact of tailor-made plasmids on large-scale manufacturing in Korea. We want to achieve the highest purity possible as a priority,” Thomas Lejolly, Asia Pacific Director at Polyplus said. “From there we will work to optimize all critical upstream raw materials to achieve highest yields and lower cost per dose for patients.”
Throughout this collaboration, the teams will also build and share local knowledge to help create a wider exchange of information and expertise to advance CGT manufacturing.
To learn more about collaborating with Polyplus in Asia, or across the globe, please visit www.polyplus-sartorius.com. Or for information on Mark Herz manufacturing capabilities, visit :http://www.markherzen.com/contents/about_company.php.
Polyplus, part of Sartorius, is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. The legacy nucleic acid delivery portfolio features process-centric transfection reagents, kits, and support services including bioproduction industry standard, PEIpro® and FectoVIR®-AAV. In 2020, the company began focusing on upstream bioprocess economic optimization with the addition of custom plasmid vector design, GMP transfection reagent and plasmid manufacturing with an internalized supply chain designed to meet strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia.
MarkHerz Inc. is a development and bio-manufacturing company for adeno-associated virus (AAV) gene therapy. MAAV, a AAV vector that delivers genetic material specifically to cardio-cerebrovascular endothelial cells, is being developed as a vaccine to prevent cardio-cerebrovascular disease in Germany and Korea. And, with the recent state support, we are developing AAV-based solid cancer target CAR-T with the bio-core team of Seoul St. Mary’s Hospital. Headquartered in Korea, the MarkHerz team continues to grow globally with operations in the Korea(APAC), Germany(EU) and UAE(MEA).
Media Contact Information:
Alengo Nyamay’antu, PhD
Marketing & Communication team leader
Direct: +33 3 88 67 59 38